Welcome to the e-CCO Library!

P736: Psychological impact of inflammatory bowel disease: differences by gender and age. The ENMENTE Project
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Gobbo Montoya M.1, Marín-Jiménez I.2, Panadero A.3, Modino Y.4, Cañas M.5, Guardiola J.6, Cea-Calvo L.7, Juliá B.7, Romero C.7, Carmona L.8, Barreiro-de Acosta M.*9

Created: Wednesday, 20 February 2019, 10:36 AM
P737 Ustekinumab induction effectiveness in Crohn’s disease in a real-life cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Sánchez Rodríguez, F. Mesonero Gismero, A. López sanroman

Created: Thursday, 30 January 2020, 10:12 AM
P737: Early life microbial exposure, lifestyle and comorbidity as risk factors for microscopic colitis: a case-control study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Verhaegh B.P.M.*1,2, Jonkers D.M.A.E.1,2, Pierik M.J.1, Masclee A.A.M.1,2, Goudkade D.3

Created: Wednesday, 20 February 2019, 10:36 AM
P737: Intensification with intravenous ustekinumab in refractory Crohn´s disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Arroyo Argüelles, J.M.(1);Suárez Ferrer, C.(2)*;Rueda García, J.L.(2);Martín-Arranz, E.(2);Poza Cordón, J.(2);Sánchez-Azofra, M.(2);García-Ramírez, L.(3);Martin-Arranz, M.D.(4);
Created: Friday, 14 July 2023, 11:12 AM
P737: SPOSIB SB2: A Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab Biosimilar SB2 (Flixabi®): interim analysis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

F. S. Macaluso*1, M. Cappello2, E. Giuffrida2, W. Fries3, A. Centritto3, A. C. Privitera4, G. Inserra5, R. Vassallo6, A. Magnano7, E. Vinci7, S. Garufi8, M. Ventimiglia1, S. Renna1, R. Orlando1, G. Rizzuto1, M. Cottone1, A. Orlando1

Created: Friday, 22 February 2019, 9:41 AM
P737: The use of infliximab therapeutic drug monitoring in virtual biologics clinic for inflammatory bowel disease (IBD) leads to clinically durable results
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Sagar1, M. Lenti1, T. Clark1, H. Rafferty1, D. Gracie1, A. Ford1, A. O'Connor1, J. Hamlin1, T. Ahmad2, C. Selinger1*

Created: Thursday, 21 February 2019, 9:14 AM
P738 Real world outcomes on the efficacy and safety of combination of biologic and immunosuppressive therapy in liver transplant recipients with inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.L. Chatzinikolaou1, N. O’Shea1, G. Erian1, A. Koutsoumpas1, J. Ryan2, M. Hamilton1, C. Murray1

Created: Thursday, 30 January 2020, 10:12 AM
P738: Assessing aCCess to investigations in IBD (ACCID) – results from an international inflammatory bowel disease survey
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ding N.S.*1,2,3, Yazdanian B.4, Bettenworth D.5, Cleynen I.6, Yassin N.A.2, Armuzzi A.7, Ferrante M.8, Zagorowicz E.S.9, Mansfield J.10, Gisbert J.11, Raine T.4

Created: Wednesday, 20 February 2019, 10:36 AM
P738: Surgery for Crohn's Disease: Results from a Spanish cohort with 15 years of follow-up
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Elosua Gonzalez, A.(1)*;Rubio, S.(2);Irisarri, R.(2);Campillo, A.(3);Nantes, Ó.(2);Vicuña, M.(2);Angós, R.(4);Zozaya, J.M.(2);Rodríguez, C.(2);
Created: Friday, 14 July 2023, 11:12 AM
P738: Sustained clinical remission with vedolizumab in Moderate-to-Severe Crohn’s disease: A GEMINI 2 post hoc analysis of Week 14 remitters
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Hardi1, B. Bokemeyer2, W. Sandborn3, W. Reinisch4, I. Shafran5, A. Stallmach6, R. Ehehalt7, P. Geransar8*, J.M. Khalid9, D. Tudor10, S. Schreiber11

Created: Thursday, 21 February 2019, 9:14 AM
P738: The budget impact of early dose optimisation with golimumab in ulcerative colitis in the UK
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Black*1, A. Hirst2, A. Brandtmüller3, S. Kachroo1, A. Puenpatom3

Created: Friday, 22 February 2019, 9:41 AM
P739 Patients with Crohn’s disease with intestinal failure have less active disease than patients with Crohn’s disease without intestinal failure
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Bouri1, J. Willsmore2, J. Geldof1, S. Gabe2, S. Donnelly2, A. Hart1

Created: Thursday, 30 January 2020, 10:12 AM
P739: Characteristic of IBD related colorectal cancers observed in different Hungarian centers
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Rutka M.*1, Farkas K.2, Tiszlavicz L.3, Szepes Z.2, Balint A.2, Bor R.2, Fábián A.3, Milassin A.2, Miheller P.4, Banai J.5, Salamon A.6, Novák J.7, Vincze A.8, Lakatos L.9, Palatka K.10, Szamosi T.5, Kovács A.11, Gelley A.12, Nagy F.2, Molnar T.2

Created: Wednesday, 20 February 2019, 10:36 AM
P739: Early use of anti-TNF in Crohn’s disease is associated with higher rate of biological and endoscopic remission
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.P. Costa Santos*, C. Gouveia, C. Palmela, C. Fidalgo, L. Glória, M. Cravo, J. Torres

Created: Thursday, 21 February 2019, 9:14 AM
P739: Sequential treatment is effective to achieve remission and avoid colectomy in moderate-to-severe Ulcerative Colitis refractory to anti-TNF therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Farkas, B.(1)*;Borsos, M.(2);Resál, T.(1);Bacsur, P.(1);Bor, R.(1);Bálint, A.(1);Fábián, A.(1);Szepes, Z.(1);Molnár, T.(1);Farkas, K.(1);
Created: Friday, 14 July 2023, 11:12 AM
P739: The progression of inflammatory bowel disease throughout Latin America: a systematic review
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Kotze*1, F. Underwood2, A. Damiao3, J. Ferraz2, R. Saad-Hossne4, M. Toro5, B. Iade6, F. Bosques-Padilla7, F. Teixeira8, F. Juliao-Baños9, D. Simian10, S. Ghosh11, R. Panaccione2, G. Kaplan2

Created: Friday, 22 February 2019, 9:41 AM
P740 Age determines the risk of familial IBD: A nationwide case–control study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Halfvarson1, J. Ludvigsson2, M. Sachs3, J. Askling3, O. Olén3

Created: Thursday, 30 January 2020, 10:12 AM
P740: Dual biologic therapy for patients with Inflammatory Bowel Disease in a single reference center in Spain
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Diz Lois Palomares, M.T.(1)*;Porta Sánchez, Á.(2);González Conde, B.(1);Estévez Prieto, E.(1);Vázquez Rey, M.T.(1);Elberdin Pazos, L.(2);Alonso Aguirre, P.(1);Martin Herranz, I.(2);
Created: Friday, 14 July 2023, 11:12 AM
P740: Efficacy and safety of vedolizumab in inflammatory bowel disease: Real-life experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. González Muñoza1, F. Mesonero2, A. Bargalló3, A. Clos4, C. Aràjol5, J. Gordillo1*, A. López- San Román2, J. Guardiola5, M. Navarro-Llavat3, F. Bertoletti1, C. Fernández2, E. Domènech4,6, E. Garcia-Planella1

Created: Thursday, 21 February 2019, 9:14 AM
P740: Sexual quality of life in inflammatory bowel disease: a multi-centre, national-level study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Roseira*1, F. Magro2, S. Fernandes3, C. Simões3, F. Portela4, V. Ana Isabel5, M. Patita5, C. Leal6, P. Lago7, P. Caldeira8, T. Gago8, P. Currais9, A. Sampaio10, C. Dias2, H. Tavares de Sousa11, GEDII1

Created: Friday, 22 February 2019, 9:41 AM